セッション

Phase Ⅱ study of Crizotinib in East Asian patients (pts) with ROS1+ advanced non-small cell lung cancer (NSCLC)

[演者] 後藤 功一:1
[著者] James CHYang:2, Dong-Wan Kim:3, Shun Lu:4, Jianying Zhou:5, 瀬戸 貴司:6, Jin-Ji Yang:7, Jolanda Paolini:8, Debasish Roychowdhury:9, Yi-Long Wu:10
1:国立がん研究センター東病院 呼吸器内科, 2:National Taiwan University Hospital and National Taiwan University Cancer Center, 3:Seoul National University Hospital, 4:Shanghai Chest Hospital, Jiao Tong University, 5:First Affiliated Hospital of Zhejiang University, 6:九州がんセンター, 7:Guangdong General Hospital, 8:Pfizer, 9:OxOnc Development, 10:Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences

Afatinib (A) vs gefitinib (G) in patients with EGFRm+ NSCLC: Updated OS data from the phase Ⅱb trial LUX-Lung 7 (LL7)

[演者] Keunchil Park:1
[著者] James Chih-Hsin Yang:2, Tony Mok:3, Eng-Huat Tan:4, O'Byrne Ken:5, Luis Paz-Ares:6, Vera Hirsh:7, Michael Boyer:8, Jean Fan:9, Li Zhang:10
1:Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2:National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan, 3:Key Laboratory of South China, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China, 4:National Cancer Centre Singapore, Singapore, 5:Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Australia, 6:Hospital Universitario Doce de Octubre and CNIO, Madrid, Spain, 7:McGill University, Montreal, Canada, 8:Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia, 9:Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 10:Cancer Center of Sun Yat-Sen University, Guangzhou, China

First-line afatinib for advanced EGFRm+ NSCLC: analysis of long-term responders (LTRs) in the LUX-Lung 3, 6 and 7 trials

[演者] James Chih-Hsin Yang:1
[著者] Luis Paz-Ares:2, Lecia V. Sequist:3, Yi-Long Wu:4, Sarayut L. Geater:5, Angela Maerten:6, Jean Fan:7, Keunchil Park:8, Martin Schuler:9
1:National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan, 2:Hospital Universitario Doce de Octubre and CNIO, Madrid, Spain, 3:Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, 4:Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China, 5:Department of Internal Medicine, Prince of Songkla University, Songkhla, Thailand, 6:Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, 7:Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA, 8:Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 9:West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany

初回治療としてEGFR-TKIを使用したEGFR遺伝子変異陽性進行非小細胞肺癌患者の早期進行が予後に及ぼす影響

[演者] 吉嗣 加奈子:1
[著者] 釼持 広知:1, 大前 勝弘:2, 大森 翔太:1, 中島 和寿:1, 和久田 一茂:1, 小野 哲:1, 内藤 立暁:1, 村上 晴泰:1, 高橋 利明:1
1:静岡県立静岡がんセンター 呼吸器内科, 2:静岡県立静岡がんセンター 臨床研究支援センター研究推進室

EGFR遺伝子変異陽性肺癌患者におけるTime to Failure of Strategyの代替エンドポイントとしての有用性の検討

[演者] 新野 祐樹:1
[著者] 後藤 悌:1, 渡邊 翔:1, 板橋 耕太:1, 神田 慎太郎:1, 堀之内 秀仁:1, 藤原 豊:1, 山本 昇:1, 大江 裕一郎:1
1:国立がん研究センター中央病院 呼吸器内科

アファチニブの高度暴露可能性が高い患者群(Special Population)の探索

[演者] 吉田 博徳:1
[著者] 山本 倫生:2, 森田 智視:2, 阪森 優一:1, 小笹 裕晃:1, 永井 宏樹:1, 関 庚三:3, 金 永学:1
1:京都大学医学部呼吸器内科, 2:京都大学大学院医学研究科医学統計生物情報学, 3:日本ベーリンガーインゲルハイム株式会社

詳細検索